Introduction and Objective: GluVue is a free application designed to enhance the efficiency of continuous glucose monitoring (CGM) data analysis for healthcare providers. Its primary goal is to improve clinical workflows and patient care in diabetes management.Methods: GluVue is designed to integrate seamlessly with electronic health records (EHR) and provide real-time analysis of continuous glucose monitoring (CGM) data. The application initiates its workflow when a healthcare provider places an order in the patient’s EHR, which triggers a connection request in the MyChart patient portal app. Upon patient or proxy acceptance, connectivity is established, allowing CGM data to be shared with Apple Health or the Health Connect app via HealthKit and subsequently integrated into the Epic EHR through MyChart. The system pulls raw glucose data from Epic and transforms it into intuitive visual formats i.e. modal-day reports, daily/weekly trend graphs, and an Ambulatory Glucose Profile display without storing data in Epic, thereby addressing potential security concerns.Results: GluVue significantly reduces the time required for CGM data interpretation, allowing clinicians to access real-time insights without the need for multiple portal logins. Users report enhanced ability to identify glucose management opportunities, leading to more informed, data-driven conversations with patients. This automated handling of CGM data increases the efficiency of reviewing patient data.Conclusion: GluVue represents a significant advancement in diabetes care by streamlining CGM data interpretation and integrating seamlessly within EHR systems. GluVue empowers healthcare providers to make more informed and timely decisions, ultimately improving patient outcomes. The implementation process can be initiated through GluVue’s Showroom webpage by submitting a request to the institution’s informatics Systems department, enabling widespread adoption of this innovative clinical tool.
K. Cefalu: Stock/Shareholder; Abbott, Dexcom, Inc.
Source link
Leave a Reply